Skip to Content

Cordis Corporation Resolves Corporate Warning Letter

MIAMI LAKES, Fla., June 14, 2007 /PRNewswire/ -- Cordis Corporation today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that all items outlined in the company's warning letter have been resolved.

"We are pleased that the FDA warning letter is now resolved," said Rick Anderson, Company Group Chairman, Cordis Corporation. "This is an important achievement for Cordis. We are committed to ensuring that our systems and procedures continue to provide for quality products and services that fulfill the clinical needs of interventional cardiologists."

About Cordis Corporation

Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in the development and manufacture of interventional vascular technology. Through the company's innovation, research and development, Cordis partners with interventional cardiologists worldwide to treat millions of patients who suffer from vascular disease.

More information about Cordis Corporation can be found at

CONTACT: Media, Christopher Allman of Cordis Corporation, +1-786-313-2303,or mobile, +1-305-586-6024, or Analysts, Louise Mehrotra, +1-732-524-6491,or Stan Panasewicz, +1-732-524-2524, or Lesley Fishman, +1-732-524-3922,all for Cordis Corporation

Web site:

Ticker Symbol: (:JNJ)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: June 2007